Key Points
- Cybin CFO Greg Cavers bought 3,000 shares at an average price of $12.91, representing a $38,730 investment and his direct ownership in the company.
- Cybin shares opened at $11.91 after declining 3.1%; the stock has traded between $3.76 and $15.15 over the past year, with a market capitalization of approximately $938 million.
- Analysts remain broadly positive, with six Buy ratings, an average target price of $46.33, and recent targets ranging from $16 to $62. However, the company missed its latest quarterly earnings estimate, reporting a loss of $0.91 per share versus expectations of $0.80.
Cybin Inc. (NASDAQ:HELP - Get Free Report) CFO Greg Cavers bought 3,000 shares of the company's stock in a transaction dated Tuesday, September 29th. The shares were acquired at an average cost of $12.91 per share, with a total value of $38,730.00. Following the acquisition, the chief financial officer directly owned 3,000 shares of the company's stock, valued at approximately $38,730. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cybin Stock Down 3.1%
Shares of NASDAQ HELP opened at $11.91 on Friday. The firm has a 50-day simple moving average of $11.67 and a 200-day simple moving average of $7.53. The stock has a market capitalization of $938.27 million, a price-to-earnings ratio of -3.94 and a beta of 0.53. Cybin Inc. has a 52 week low of $3.76 and a 52 week high of $15.15.
Cybin (NASDAQ:HELP - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). As a group, equities research analysts expect that Cybin Inc. will post -2.95 EPS for the current year.
Analyst Ratings Changes
HELP has been the topic of several recent research reports. Wells Fargo & Company assumed coverage on Cybin in a report on Monday, July 27th. They set an "overweight" rating and a $16.00 target price on the stock. TD Cowen upped their price target on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. Wall Street Zen raised Cybin from a "strong sell" rating to a "sell" rating in a report on Saturday, August 29th. Finally, Barclays assumed coverage on Cybin in a research report on Friday, September 18th. They set an "overweight" rating and a $35.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $46.33.
View Our Latest Stock Analysis on HELP
Institutional Investors Weigh In On Cybin
An institutional investor recently bought a new stake in Cybin stock. AXQ Capital LP bought a new position in shares of Cybin Inc. (NASDAQ:HELP - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,315 shares of the company's stock, valued at approximately $75,000. Hedge funds and other institutional investors own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.
Cybin's development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
